首页 > 最新文献

Journal of Hepatocellular Carcinoma最新文献

英文 中文
CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils CXCL9过表达可预测HCC对抗PD-1疗法的反应并促进中性粒细胞的N1极化
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-05-08 DOI: 10.2147/jhc.s450468
Pei Wang, Ming-Hao Xu, Wen-Xin Xu, Zi-Ying Dong, Ying-Hao Shen, Wen-Zheng Qin
Background: Anti-programmed death-1 (PD1) antibodies have changed the treatment landscape for hepatocellular carcinoma (HCC) and exhibit promising treatment efficacy. However, the majority of HCCs still do not respond to anti-PD-1 therapy.
Methods: We analyzed the expression of CXCL9 in blood samples from patients who received anti-PD-1 therapy and evaluated its correlation with clinicopathological characteristics and treatment outcomes. Based on the results of Cox regression analysis, a nomogram was established for predicting HCC response to anti-PD-1 therapy. qRT‒PCR and multiple immunofluorescence assays were utilized to analyze the proportions of N1-type neutrophils in vitro and in tumor samples, respectively.
Results: The nomogram showed good predictive efficacy in the training and validation cohorts and may be useful for guiding clinical treatment of HCC patients. We also found that HCC cell-derived CXCL9 promoted N1 polarization of neutrophils in vitro and that AMG487, a specific CXCR3 inhibitor, significantly blocked this process. Moreover, multiple immunofluorescence (mIF) showed that patients with higher serum CXCL9 levels had greater infiltration of the N1 phenotype of tumor-associated neutrophils (TANs).
Conclusion: Our study highlights the critical role of CXCL9 as an effective biomarker of immunotherapy efficacy and in promoting the polarization of N1-type neutrophils; thus, targeting the CXCL9-CXCR3 axis could represent a novel pharmaceutical strategy to enhance immunotherapy for HCC.

背景:抗程序性死亡-1(PD1)抗体改变了肝细胞癌(HCC)的治疗格局,并显示出良好的疗效。然而,大多数肝细胞癌仍然对抗PD-1疗法没有反应:我们分析了接受抗PD-1治疗的患者血液样本中CXCL9的表达,并评估了其与临床病理特征和治疗结果的相关性。利用 qRT-PCR 和多重免疫荧光检测法分别分析了体外和肿瘤样本中 N1 型中性粒细胞的比例:结果:该提名图在训练组和验证组中显示出良好的预测效果,可用于指导 HCC 患者的临床治疗。我们还发现,HCC 细胞衍生的 CXCL9 在体外促进了中性粒细胞的 N1 极化,而特异性 CXCR3 抑制剂 AMG487 能显著阻断这一过程。此外,多重免疫荧光(mIF)显示,血清中CXCL9水平较高的患者,其肿瘤相关中性粒细胞(TANs)的N1表型浸润程度更高:我们的研究强调了CXCL9作为免疫疗法疗效的有效生物标志物以及在促进N1型中性粒细胞极化方面的关键作用;因此,以CXCL9-CXCR3轴为靶点可能是加强HCC免疫疗法的一种新型药物策略。
{"title":"CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils","authors":"Pei Wang, Ming-Hao Xu, Wen-Xin Xu, Zi-Ying Dong, Ying-Hao Shen, Wen-Zheng Qin","doi":"10.2147/jhc.s450468","DOIUrl":"https://doi.org/10.2147/jhc.s450468","url":null,"abstract":"<strong>Background:</strong> Anti-programmed death-1 (PD1) antibodies have changed the treatment landscape for hepatocellular carcinoma (HCC) and exhibit promising treatment efficacy. However, the majority of HCCs still do not respond to anti-PD-1 therapy.<br/><strong>Methods:</strong> We analyzed the expression of CXCL9 in blood samples from patients who received anti-PD-1 therapy and evaluated its correlation with clinicopathological characteristics and treatment outcomes. Based on the results of Cox regression analysis, a nomogram was established for predicting HCC response to anti-PD-1 therapy. qRT‒PCR and multiple immunofluorescence assays were utilized to analyze the proportions of N1-type neutrophils in vitro and in tumor samples, respectively.<br/><strong>Results:</strong> The nomogram showed good predictive efficacy in the training and validation cohorts and may be useful for guiding clinical treatment of HCC patients. We also found that HCC cell-derived CXCL9 promoted N1 polarization of neutrophils in vitro and that AMG487, a specific CXCR3 inhibitor, significantly blocked this process. Moreover, multiple immunofluorescence (mIF) showed that patients with higher serum CXCL9 levels had greater infiltration of the N1 phenotype of tumor-associated neutrophils (TANs).<br/><strong>Conclusion:</strong> Our study highlights the critical role of CXCL9 as an effective biomarker of immunotherapy efficacy and in promoting the polarization of N1-type neutrophils; thus, targeting the CXCL9-CXCR3 axis could represent a novel pharmaceutical strategy to enhance immunotherapy for HCC.<br/><br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"61 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140882431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns, Risk Factors, and Outcomes of Recurrence After Hepatectomy for Hepatocellular Carcinoma with and without Microvascular Invasion. 伴有或不伴有微血管侵犯的肝细胞癌肝脏切除术后复发的模式、风险因素和预后。
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S438850
Yang Yu, Xiao-Hui Wang, Wen-Jie Hu, De-Hua Chen, Zi-Li Hu, Shao-Qiang Li

Purpose: The patterns and risk factors of postsurgical recurrence of patient with hepatocellular carcinoma (HCC) with microvascular invasion (MVI) are not clarified. This study aimed to decipher and compare the postoperative recurrent patterns and the risk factors contributing to recurrence between MVI positive (MVI(+)) and MVI negative (MVI(-)) HCC after hepatectomy.

Patients and methods: Patients with HCC who underwent hepatectomy in three Chinese academic hospitals between January 1, 2009, and December 31, 2018, were enrolled. Recurrent patterns included early (≤2 years) or late (>2 years) recurrence, recurrent sites and number, and risk factors of recurrence were compared between the MVI(+)and MVI(-) groups by propensity score-matching (PSM).

Results: Of 1756 patients included, 581 (33.1%) were MVI(+), and 875 (49.8%) patients developed early recurrence. Compared with the MVI(-) group, the MVI(+) group had a higher 2-year recurrence rate in the PSM cohort (hazard ratio [HR], 1.82; 95% confidence interval [CI], 1.59-2.10; P < 0.001), and more patients with multiple tumor recurrence. Patients with early recurrence in the MVI(+) group had a worse overall survival (OS) than those in the MVI(-) group (HR, 1.24; 95% CI, 1.02-1.50; P = 0.034). Resection margin (RM) ≤1.0 cm is a surgical predictor of early recurrence for the MVI(+) group (HR, 0.68; 95% CI, 0.54-0.87; P = 0.002), but not for the MVI(-) group.

Conclusion: Compared to MVI(-) HCC, MVI(+) HCC tends to be early, multiple recurrence and lung and lymph node metastasis after resection. RM ≤1.0 cm is a surgical risk factor of early recurrence for patient with MVI.

目的:微血管侵犯(MVI)肝细胞癌(HCC)患者术后复发的模式和风险因素尚未明确。本研究旨在解读和比较微血管侵犯阳性(MVI(+))和微血管侵犯阴性(MVI(-))肝癌患者肝切除术后的术后复发模式和导致复发的风险因素。患者和方法:纳入2009年1月1日至2018年12月31日期间在中国三家学术医院接受肝切除术的HCC患者。复发模式包括早期(≤2年)或晚期(>2年)复发、复发部位和数量,并通过倾向得分匹配(PSM)比较了MVI(+)组与MVI(-)组之间的复发风险因素:结果:在纳入的1756例患者中,581例(33.1%)为MVI(+),875例(49.8%)为早期复发。与MVI(-)组相比,MVI(+)组在PSM队列中的2年复发率更高(危险比[HR],1.82;95%置信区间[CI],1.59-2.10;P<0.001),且多发肿瘤复发患者更多。MVI(+)组早期复发患者的总生存率(OS)低于MVI(-)组(HR,1.24;95% CI,1.02-1.50;P = 0.034)。切除边缘(RM)≤1.0厘米是MVI(+)组早期复发的手术预测因子(HR,0.68;95% CI,0.54-0.87;P = 0.002),而MVI(-)组则不是:结论:与 MVI(-)HCC 相比,MVI(+)HCC 更倾向于早期、多次复发以及切除后的肺转移和淋巴结转移。RM≤1.0厘米是MVI患者早期复发的手术风险因素。
{"title":"Patterns, Risk Factors, and Outcomes of Recurrence After Hepatectomy for Hepatocellular Carcinoma with and without Microvascular Invasion.","authors":"Yang Yu, Xiao-Hui Wang, Wen-Jie Hu, De-Hua Chen, Zi-Li Hu, Shao-Qiang Li","doi":"10.2147/JHC.S438850","DOIUrl":"10.2147/JHC.S438850","url":null,"abstract":"<p><strong>Purpose: </strong>The patterns and risk factors of postsurgical recurrence of patient with hepatocellular carcinoma (HCC) with microvascular invasion (MVI) are not clarified. This study aimed to decipher and compare the postoperative recurrent patterns and the risk factors contributing to recurrence between MVI positive (MVI<sup>(+)</sup>) and MVI negative (MVI<sup>(-)</sup>) HCC after hepatectomy.</p><p><strong>Patients and methods: </strong>Patients with HCC who underwent hepatectomy in three Chinese academic hospitals between January 1, 2009, and December 31, 2018, were enrolled. Recurrent patterns included early (≤2 years) or late (>2 years) recurrence, recurrent sites and number, and risk factors of recurrence were compared between the MVI<sup>(+)</sup>and MVI<sup>(-)</sup> groups by propensity score-matching (PSM).</p><p><strong>Results: </strong>Of 1756 patients included, 581 (33.1%) were MVI<sup>(+)</sup>, and 875 (49.8%) patients developed early recurrence. Compared with the MVI<sup>(-)</sup> group, the MVI<sup>(+)</sup> group had a higher 2-year recurrence rate in the PSM cohort (hazard ratio [HR], 1.82; 95% confidence interval [CI], 1.59-2.10; P < 0.001), and more patients with multiple tumor recurrence. Patients with early recurrence in the MVI<sup>(+)</sup> group had a worse overall survival (OS) than those in the MVI<sup>(-)</sup> group (HR, 1.24; 95% CI, 1.02-1.50; P = 0.034). Resection margin (RM) ≤1.0 cm is a surgical predictor of early recurrence for the MVI<sup>(+)</sup> group (HR, 0.68; 95% CI, 0.54-0.87; P = 0.002), but not for the MVI<sup>(-)</sup> group.</p><p><strong>Conclusion: </strong>Compared to MVI<sup>(-)</sup> HCC, MVI<sup>(+)</sup> HCC tends to be early, multiple recurrence and lung and lymph node metastasis after resection. RM ≤1.0 cm is a surgical risk factor of early recurrence for patient with MVI.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"801-812"},"PeriodicalIF":4.1,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulating NK Cell Infiltration. PVALB被确定为与免疫密切相关的HCC独立预后因子,其缺失会通过调节NK细胞浸润加速肿瘤进展。
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.2147/JHC.S450479
Yiyang Gong, Minqin Zhou, Yanting Zhu, Jingying Pan, Xuanrui Zhou, Yike Jiang, Hong Zeng, Hao Zheng, Xitong Geng, Da Huang

Purpose: Hepatocellular carcinoma is the most common primary liver cancer, with poor prognosis. Complex immune microenvironment of the liver is linked to the development of HCC. PVALB is a calcium-binding protein which has been described as a cancer suppressor gene in thyroid cancer and glioma. Nevertheless, the role of PVALB in HCC is unknown.

Materials and methods: We obtained data from TCGA and GSE54236 datasets. MCP-counter, WGCNA and LASSO model were applied to identify PVALB. With UALCAN, MethSurv, and other websites, we probed the expression, methylation and survival of PVALB. LinkedOmics and GSEA were adopted for functional analysis, while TIMER, TISIDB, Kaplan-Meier plotter, TIDE databases were utilized to evaluate the relevance of PVALB to the tumor immune microenvironment and predict immunotherapy efficacy. TargetScan, DIANA, LncRNASNP2 databases and relevant experiments were employed to construct ceRNA network. Finally, molecular docking and drug sensitivity of PVALB were characterized by GeneMANIA, CTD, and so on.

Results: PVALB was recognized as a gene associated with HCC and NK cell. Its expression was down-regulated in HCC tissue, which lead to adverse prognosis. Besides, the hypomethylation of PVALB was related to its reduced expression. Notably, PVALB was tightly linked to immune, and its reduced expression attenuated the anticancer effect of NK cells via the Fas/FasL pathway, leading to a adverse outcome. The lnc-YY1AP1-3/hsa-miR-6735-5p/PVALB axis may regulate the PVALB expression. Finally, we found immunotherapy might be a viable treatment option.

Conclusion: In a word, PVALB is a prognostic indicator, whose low expression facilitates HCC progression by impacting NK cell infiltration.

目的:肝细胞癌是最常见的原发性肝癌,预后不良。肝脏复杂的免疫微环境与 HCC 的发展有关。PVALB是一种钙结合蛋白,已被描述为甲状腺癌和胶质瘤的抑癌基因。然而,PVALB 在 HCC 中的作用尚不清楚:我们从 TCGA 和 GSE54236 数据集中获取数据。应用 MCP-counter、WGCNA 和 LASSO 模型识别 PVALB。通过 UALCAN、MethSurv 和其他网站,我们探究了 PVALB 的表达、甲基化和存活情况。采用LinkedOmics和GSEA进行功能分析,利用TIMER、TISIDB、Kaplan-Meier plotter和TIDE数据库评估PVALB与肿瘤免疫微环境的相关性,预测免疫治疗的疗效。利用TargetScan、DIANA、LncRNASNP2数据库和相关实验构建了ceRNA网络。最后,通过GeneMANIA、CTD等对PVALB的分子对接和药物敏感性进行了表征:结果:PVALB被认为是与HCC和NK细胞相关的基因。结果:PVALB 被认为是与 HCC 和 NK 细胞相关的基因,它在 HCC 组织中的表达下调,导致不良预后。此外,PVALB的低甲基化与其表达减少有关。值得注意的是,PVALB与免疫密切相关,它的表达减少会削弱NK细胞通过Fas/FasL途径的抗癌作用,从而导致不良预后。lnc-YY1AP1-3/hsa-miR-6735-5p/PVALB轴可能调控PVALB的表达。最后,我们发现免疫疗法可能是一种可行的治疗方案:总而言之,PVALB是一个预后指标,其低表达通过影响NK细胞浸润而促进HCC的进展。
{"title":"PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulating NK Cell Infiltration.","authors":"Yiyang Gong, Minqin Zhou, Yanting Zhu, Jingying Pan, Xuanrui Zhou, Yike Jiang, Hong Zeng, Hao Zheng, Xitong Geng, Da Huang","doi":"10.2147/JHC.S450479","DOIUrl":"10.2147/JHC.S450479","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma is the most common primary liver cancer, with poor prognosis. Complex immune microenvironment of the liver is linked to the development of HCC. PVALB is a calcium-binding protein which has been described as a cancer suppressor gene in thyroid cancer and glioma. Nevertheless, the role of PVALB in HCC is unknown.</p><p><strong>Materials and methods: </strong>We obtained data from TCGA and GSE54236 datasets. MCP-counter, WGCNA and LASSO model were applied to identify PVALB. With UALCAN, MethSurv, and other websites, we probed the expression, methylation and survival of PVALB. LinkedOmics and GSEA were adopted for functional analysis, while TIMER, TISIDB, Kaplan-Meier plotter, TIDE databases were utilized to evaluate the relevance of PVALB to the tumor immune microenvironment and predict immunotherapy efficacy. TargetScan, DIANA, LncRNASNP2 databases and relevant experiments were employed to construct ceRNA network. Finally, molecular docking and drug sensitivity of PVALB were characterized by GeneMANIA, CTD, and so on.</p><p><strong>Results: </strong>PVALB was recognized as a gene associated with HCC and NK cell. Its expression was down-regulated in HCC tissue, which lead to adverse prognosis. Besides, the hypomethylation of PVALB was related to its reduced expression. Notably, PVALB was tightly linked to immune, and its reduced expression attenuated the anticancer effect of NK cells via the Fas/FasL pathway, leading to a adverse outcome. The lnc-YY1AP1-3/hsa-miR-6735-5p/PVALB axis may regulate the PVALB expression. Finally, we found immunotherapy might be a viable treatment option.</p><p><strong>Conclusion: </strong>In a word, PVALB is a prognostic indicator, whose low expression facilitates HCC progression by impacting NK cell infiltration.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"813-838"},"PeriodicalIF":4.1,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors 一种强调薄缘 APHE 的改良 Targetoid 特征可提高 LI-RADS 对恶性肝肿瘤的诊断性能
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-26 DOI: 10.2147/jhc.s448257
Runqian Huang, Chunling Zheng, Guixiao Xu, Xuanwei Chen, Jingxian Shen, Siyue Mao
Objective: To identify imaging features that help distinguish between HCCs and non-HCC malignancies assigned to LI-RADS M (LR-M) and evaluate the diagnostic performance of a LI-RADS with targetoid criteria using thin-rim arterial phase hyperenhancement (APHE).
Materials and Methods: This retrospective study included 381 patients (387 observations) at high-risk for HCC who underwent enhanced-MRI before surgery. Three radiologists reviewed images for LI-RADS categorization of hepatic observations. Univariate and multivariate analysis was conducted to determine reliable features to differentiate between HCC and non-HCC malignancies among the LR-M lesions. The thin-rim (< 30%) APHE was defined based on the thickest thickness of rim APHE compared with the tumor radius, and a modified LI-RADS emphasizing thin-rim APHE as a specific feature of LR-M was established. We compared the diagnostic performance of modified LR-M and LI-RADS 5 (LR-5) with the conventional one.
Results: Thin-rim APHE and targetoid diffusion-weighted imaging (DWI) were found as independent predictive factors of non-HCC malignancies, while enhancing capsule, thick-rim APHE and peripheral washout were noted as independent variables significantly associated with HCC of LR-M (P< 0.05). The noticeable diagnostic performance of thin-rim APHE in distinguishing non-HCC malignancies from HCCs using the ROC curve. Emphasizing thin-rim APHE on targetoid features, the modified LR-M revealed significantly superior specificity and accuracy (89.4% vs 81.1%, P=0.004; and 87.9% vs 82.2%, P=0.027, respectively) while maintaining high sensitivity (82.2% vs 86.0%; P=0.529) compared with the LR-M. Meanwhile, the modified LR-5 achieved greater sensitivity and accuracy (88.6% vs 79.7%, P=0.004; and 85.8% vs 80.1%, P=0.036, respectively) for diagnosing HCC, without compromising specificity (78.3% vs.81.1%; P=0.608) compared with the LR-5.
Conclusion: Thin-rim APHE may be the specific imaging feature for differentiating non-HCC malignancies from HCCs within LR-M. The modified targetoid criteria emphasizing thin-rim APHE can improve the diagnostic performance of LI-RADS for hepatic malignancies.

Keywords: hepatic tumors, malignant, targetoid feature, Rim APHE, liver imaging reporting and data system
目的确定有助于区分HCC和被归入LI-RADS M(LR-M)的非HCC恶性肿瘤的成像特征,并评估使用薄缘动脉相增强(APHE)的LI-RADS的诊断性能:这项回顾性研究纳入了 381 例(观察 387 例)HCC 高危患者,他们都在手术前接受了增强型 MRI 检查。三名放射科医生对图像进行了审查,以便对肝脏观察结果进行 LI-RADS 分类。我们进行了单变量和多变量分析,以确定在 LR-M 病变中区分 HCC 和非 HCC 恶性肿瘤的可靠特征。根据APHE边缘与肿瘤半径相比的最厚厚度定义了薄边缘(< 30% )APHE,并建立了强调薄边缘APHE作为LR-M特异特征的改良LI-RADS。我们比较了改良 LR-M 和 LI-RADS 5(LR-5)与传统 LR-M 的诊断性能:结果:发现薄缘 APHE 和靶状弥散加权成像(DWI)是非 HCC 恶性肿瘤的独立预测因素,而增强囊、厚缘 APHE 和外周冲洗是与 LR-M HCC 显著相关的独立变量(P< 0.05)。利用 ROC 曲线,薄缘 APHE 在区分非 HCC 恶性肿瘤和 HCC 方面具有明显的诊断性能。与 LR-M 相比,强调薄层 APHE 靶状特征的改良 LR-M 在保持高灵敏度(82.2% vs 86.0%;P=0.529)的同时,特异性和准确性也明显优于 LR-M(分别为 89.4% vs 81.1%,P=0.004;87.9% vs 82.2%,P=0.027)。同时,与 LR-5 相比,改良 LR-5 诊断 HCC 的灵敏度和准确性更高(分别为 88.6% vs 79.7%,P=0.004;85.8% vs 80.1%,P=0.036),而特异性(78.3% vs 81.1%;P=0.608)却没有降低:薄缘 APHE 可能是 LR-M 鉴别非 HCC 恶性肿瘤和 HCC 的特异性成像特征。关键词:肝脏肿瘤;恶性;类靶组织特征;Rim APHE;肝脏成像报告和数据系统
{"title":"A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors","authors":"Runqian Huang, Chunling Zheng, Guixiao Xu, Xuanwei Chen, Jingxian Shen, Siyue Mao","doi":"10.2147/jhc.s448257","DOIUrl":"https://doi.org/10.2147/jhc.s448257","url":null,"abstract":"<strong>Objective:</strong> To identify imaging features that help distinguish between HCCs and non-HCC malignancies assigned to LI-RADS M (LR-M) and evaluate the diagnostic performance of a LI-RADS with targetoid criteria using thin-rim arterial phase hyperenhancement (APHE).<br/><strong>Materials and Methods:</strong> This retrospective study included 381 patients (387 observations) at high-risk for HCC who underwent enhanced-MRI before surgery. Three radiologists reviewed images for LI-RADS categorization of hepatic observations. Univariate and multivariate analysis was conducted to determine reliable features to differentiate between HCC and non-HCC malignancies among the LR-M lesions. The thin-rim (&lt; 30%) APHE was defined based on the thickest thickness of rim APHE compared with the tumor radius, and a modified LI-RADS emphasizing thin-rim APHE as a specific feature of LR-M was established. We compared the diagnostic performance of modified LR-M and LI-RADS 5 (LR-5) with the conventional one.<br/><strong>Results:</strong> Thin-rim APHE and targetoid diffusion-weighted imaging (DWI) were found as independent predictive factors of non-HCC malignancies, while enhancing capsule, thick-rim APHE and peripheral washout were noted as independent variables significantly associated with HCC of LR-M (<em>P</em>&lt; 0.05). The noticeable diagnostic performance of thin-rim APHE in distinguishing non-HCC malignancies from HCCs using the ROC curve. Emphasizing thin-rim APHE on targetoid features, the modified LR-M revealed significantly superior specificity and accuracy (89.4% vs 81.1%, <em>P</em>=0.004; and 87.9% vs 82.2%, <em>P</em>=0.027, respectively) while maintaining high sensitivity (82.2% vs 86.0%; <em>P</em>=0.529) compared with the LR-M. Meanwhile, the modified LR-5 achieved greater sensitivity and accuracy (88.6% vs 79.7%, <em>P</em>=0.004; and 85.8% vs 80.1%, <em>P</em>=0.036, respectively) for diagnosing HCC, without compromising specificity (78.3% vs.81.1%; <em>P</em>=0.608) compared with the LR-5.<br/><strong>Conclusion:</strong> Thin-rim APHE may be the specific imaging feature for differentiating non-HCC malignancies from HCCs within LR-M. The modified targetoid criteria emphasizing thin-rim APHE can improve the diagnostic performance of LI-RADS for hepatic malignancies.<br/><br/><strong>Keywords:</strong> hepatic tumors, malignant, targetoid feature, Rim APHE, liver imaging reporting and data system<br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"16 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140800435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triglyceride-Glucose Index is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients with HBV-Related Liver Cirrhosis 甘油三酯-葡萄糖指数是 HBV 相关性肝硬化患者发生肝细胞癌的独立风险因素
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-18 DOI: 10.2147/jhc.s454037
Su-Hua Yang, Yi-Shan He, Shu-Qin Zheng, Xiu-Jun Zhang, Hong Dai, Yuan Xue
Aim: This study aimed to explore the effects of the triglyceride-glucose (TyG) index on hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related liver cirrhosis (LC).
Methods: A total of 242 patients with HBV-related LC were enrolled and followed-up. Logistic regression analysis was performed to investigate risk factors for HCC.
Results: The median follow-up time was 37 months (range: 6– 123 months). At the end of the follow-up, 11 (11.3%) patients with compensated cirrhosis (CC) and 45 (31.0%) with decompensated cirrhosis (DC) developed HCC. The TyG index was higher in the HCC group than in the non-HCC group (P=0.05). Univariate analysis showed that age (P< 0.01), DC (P< 0.01), TyG index (P=0.08), albumin (ALB) level (P=0.05), platelet (PLT) count (P< 0.01), and HBV DNA positivity (P< 0.01) were associated with HCC development. Multivariate analysis revealed that age, DC, TyG index, PLT count, and HBV DNA positivity were independent risk factors for HCC development (P=0.01, 0.01, < 0.01, 0.05, and < 0.01, respectively). For patients with DC, multivariate logistic regression analysis revealed that age, TyG index, and HBV DNA positivity were independent risk factors for HCC development (all P< 0.05). A new model encompassing age, DC, TyG, PLT, and positive HBV DNA had optimal predictive accuracy in patients with DC or CC, with a cutoff value of 0.197. The areas under the receiver operating characteristic curves (AUROCs) of the model for predicting HCC development in patients with LC, DC, and CC were 0.778, 0.721, and 0.783, respectively.
Conclusion: TyG index was identified as an independent risk factor for HCC development in patients with LC.

Keywords: hepatocellular carcinoma, triglyceride-glucose index, insulin resistance, liver cirrhosis, decompensated cirrhosis
目的:本研究旨在探讨甘油三酯-葡萄糖(TyG)指数对乙型肝炎病毒(HBV)相关肝硬化(LC)患者肝细胞癌(HCC)发展的影响:方法:共登记并随访了242例HBV相关肝硬化患者。结果:中位随访时间为 37 个月:中位随访时间为 37 个月(6-123 个月)。随访结束时,11 例(11.3%)代偿期肝硬化(CC)患者和 45 例(31.0%)失代偿期肝硬化(DC)患者发展为 HCC。HCC 组的 TyG 指数高于非 HCC 组(P=0.05)。单变量分析显示,年龄(P< 0.01)、DC(P< 0.01)、TyG 指数(P=0.08)、白蛋白(ALB)水平(P=0.05)、血小板(PLT)计数(P< 0.01)和 HBV DNA 阳性(P< 0.01)与 HCC 的发生有关。多变量分析表明,年龄、DC、TyG 指数、PLT 计数和 HBV DNA 阳性是 HCC 发生的独立危险因素(分别为 P=0.01、0.01、< 0.01、0.05 和 < 0.01)。对于 DC 患者,多变量逻辑回归分析显示,年龄、TyG 指数和 HBV DNA 阳性是 HCC 发生的独立危险因素(均为 P<0.05)。一个包含年龄、DC、TyG、PLT 和 HBV DNA 阳性的新模型对 DC 或 CC 患者具有最佳预测准确性,临界值为 0.197。该模型预测LC、DC和CC患者发生HCC的接收者操作特征曲线下面积(AUROCs)分别为0.778、0.721和0.783:关键词:肝细胞癌;甘油三酯-葡萄糖指数;胰岛素抵抗;肝硬化;失代偿期肝硬化
{"title":"Triglyceride-Glucose Index is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients with HBV-Related Liver Cirrhosis","authors":"Su-Hua Yang, Yi-Shan He, Shu-Qin Zheng, Xiu-Jun Zhang, Hong Dai, Yuan Xue","doi":"10.2147/jhc.s454037","DOIUrl":"https://doi.org/10.2147/jhc.s454037","url":null,"abstract":"<strong>Aim:</strong> This study aimed to explore the effects of the triglyceride-glucose (TyG) index on hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related liver cirrhosis (LC).<br/><strong>Methods:</strong> A total of 242 patients with HBV-related LC were enrolled and followed-up. Logistic regression analysis was performed to investigate risk factors for HCC.<br/><strong>Results:</strong> The median follow-up time was 37 months (range: 6– 123 months). At the end of the follow-up, 11 (11.3%) patients with compensated cirrhosis (CC) and 45 (31.0%) with decompensated cirrhosis (DC) developed HCC. The TyG index was higher in the HCC group than in the non-HCC group (P=0.05). Univariate analysis showed that age (P&lt; 0.01), DC (P&lt; 0.01), TyG index (P=0.08), albumin (ALB) level (P=0.05), platelet (PLT) count (P&lt; 0.01), and HBV DNA positivity (P&lt; 0.01) were associated with HCC development. Multivariate analysis revealed that age, DC, TyG index, PLT count, and HBV DNA positivity were independent risk factors for HCC development (P=0.01, 0.01, &lt; 0.01, 0.05, and &lt; 0.01, respectively). For patients with DC, multivariate logistic regression analysis revealed that age, TyG index, and HBV DNA positivity were independent risk factors for HCC development (all P&lt; 0.05). A new model encompassing age, DC, TyG, PLT, and positive HBV DNA had optimal predictive accuracy in patients with DC or CC, with a cutoff value of 0.197. The areas under the receiver operating characteristic curves (AUROCs) of the model for predicting HCC development in patients with LC, DC, and CC were 0.778, 0.721, and 0.783, respectively.<br/><strong>Conclusion:</strong> TyG index was identified as an independent risk factor for HCC development in patients with LC.<br/><br/><strong>Keywords:</strong> hepatocellular carcinoma, triglyceride-glucose index, insulin resistance, liver cirrhosis, decompensated cirrhosis<br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"1 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140617600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study 巨大肝细胞癌辅助经动脉化疗栓塞加免疫疗法:倾向得分匹配队列研究
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-08 DOI: 10.2147/jhc.s455878
Hongwei Huang, Wei Liao, Kaiyue Zhang, Hao Wang, Qi Cheng, Bin Mei
Purpose: The prognosis of patients with huge hepatocellular carcinoma (huge HCC, diameter ≥ 10 cm) is poor owing to the high early recurrence rate. This study aimed to explore the clinical value of postoperative adjuvant transarterial chemoembolization (PA-TACE) plus programmed cell death-1 (PD-1) inhibitors for huge HCC.
Patients and Methods: Data from consecutive huge HCC patients treated with hepatectomy during June 2017 and July 2022 were retrospectively collected. Baseline differences were balanced between huge HCC patients who underwent PA-TACE with (AIT group) or without PD-1 inhibitors (AT group) by propensity-score matching (PSM). We compared recurrence-free survival (RFS), overall survival (OS) and recurrence patterns between the two groups. Independent risk factors for RFS and OS were confirmed by Cox regression analysis, and subgroup analysis was also conducted.
Results: A total of 294 patients were enrolled, and 77 pairs of patients in the AIT and AT groups were matched by PSM. The 1-year and 2-year RFS were 49.9% and 35.7% in the AIT group compared to 24.7% and 15.5% in the AT group respectively (p< 0.001). The 1-year and 2-year OS were 83.6% and 66.9% in the AIT group compared to 50.6% and 36.8% in the AT group respectively (p< 0.001). There were no significant differences in recurrence patterns between the two groups. Multivariable analysis demonstrated that combined therapy of PA-TACE plus PD-1 inhibitors was a protective factor related to both RFS and OS.
Conclusion: PA-TACE plus PD-1 inhibitors could improve survival outcomes for huge HCC patients.

Keywords: hepatocellular carcinoma, postoperative adjuvant therapy, programmed cell death-1 inhibitors, transarterial chemoembolization, early recurrence
目的:巨大肝细胞癌(巨大HCC,直径≥10厘米)患者由于早期复发率高而预后较差。本研究旨在探讨巨大肝细胞癌术后辅助经动脉化疗栓塞(PA-TACE)加程序性细胞死亡-1(PD-1)抑制剂的临床价值:回顾性收集2017年6月至2022年7月期间接受肝切除术治疗的连续巨大HCC患者的数据。通过倾向分数匹配(PSM)平衡了接受PA-TACE治疗并使用(AIT组)或不使用PD-1抑制剂(AT组)的巨大HCC患者之间的基线差异。我们比较了两组患者的无复发生存期(RFS)、总生存期(OS)和复发模式。通过Cox回归分析确认了RFS和OS的独立风险因素,并进行了亚组分析:共有294名患者入组,77对AIT组和AT组患者进行了PSM配对。AIT组的1年和2年RFS分别为49.9%和35.7%,而AT组分别为24.7%和15.5%(p< 0.001)。AIT组的1年和2年OS分别为83.6%和66.9%,而AT组分别为50.6%和36.8%(p< 0.001)。两组的复发模式无明显差异。多变量分析表明,PA-TACE加PD-1抑制剂的联合治疗是RFS和OS的保护因素:PA-TACE加PD-1抑制剂可改善巨大HCC患者的生存预后。 关键词:肝细胞癌;术后辅助治疗;程序性细胞死亡-1抑制剂;经动脉化疗栓塞;早期复发
{"title":"Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study","authors":"Hongwei Huang, Wei Liao, Kaiyue Zhang, Hao Wang, Qi Cheng, Bin Mei","doi":"10.2147/jhc.s455878","DOIUrl":"https://doi.org/10.2147/jhc.s455878","url":null,"abstract":"<strong>Purpose:</strong> The prognosis of patients with huge hepatocellular carcinoma (huge HCC, diameter ≥ 10 cm) is poor owing to the high early recurrence rate. This study aimed to explore the clinical value of postoperative adjuvant transarterial chemoembolization (PA-TACE) plus programmed cell death-1 (PD-1) inhibitors for huge HCC.<br/><strong>Patients and Methods:</strong> Data from consecutive huge HCC patients treated with hepatectomy during June 2017 and July 2022 were retrospectively collected. Baseline differences were balanced between huge HCC patients who underwent PA-TACE with (AIT group) or without PD-1 inhibitors (AT group) by propensity-score matching (PSM). We compared recurrence-free survival (RFS), overall survival (OS) and recurrence patterns between the two groups. Independent risk factors for RFS and OS were confirmed by Cox regression analysis, and subgroup analysis was also conducted.<br/><strong>Results:</strong> A total of 294 patients were enrolled, and 77 pairs of patients in the AIT and AT groups were matched by PSM. The 1-year and 2-year RFS were 49.9% and 35.7% in the AIT group compared to 24.7% and 15.5% in the AT group respectively (p&lt; 0.001). The 1-year and 2-year OS were 83.6% and 66.9% in the AIT group compared to 50.6% and 36.8% in the AT group respectively (p&lt; 0.001). There were no significant differences in recurrence patterns between the two groups. Multivariable analysis demonstrated that combined therapy of PA-TACE plus PD-1 inhibitors was a protective factor related to both RFS and OS.<br/><strong>Conclusion:</strong> PA-TACE plus PD-1 inhibitors could improve survival outcomes for huge HCC patients.<br/><br/><strong>Keywords:</strong> hepatocellular carcinoma, postoperative adjuvant therapy, programmed cell death-1 inhibitors, transarterial chemoembolization, early recurrence<br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"550 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140572779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Macroscopic Characterization of Hepatocellular Carcinoma: An Underexploited Source of Prognostic Factors 肝细胞癌的宏观特征:未被充分利用的预后因素来源
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-06 DOI: 10.2147/jhc.s447848
Stéphanie Gonvers, Sebastiao N Martins-Filho, André Hirayama, Julien Calderaro, Rebecca Phillips, Emilie Uldry, Nicolas Demartines, Emmanuel Melloul, Young Nyun Park, Valérie Paradis, Swan N Thung, Venancio Alves, Christine Sempoux, Ismail Labgaa
Abstract: The macroscopic appearance of a tumor such as hepatocellular carcinoma (HCC) may be defined as its phenotype which is de facto dictated by its genotype. Therefore, macroscopic characteristics of HCC are unlikely random but rather reflect genomic traits of cancer, presumably acting as a valuable source of information that can be retrieved and exploited to infer prognosis. This review aims to provide a comprehensive overview of the available data on the prognostic value of macroscopic characterization in HCC. A total of 57 studies meeting eligible criteria were identified, including patients undergoing liver resection (LR; 47 studies, 83%) or liver transplant (LT; 9 studies, 16%). The following macroscopic variables were investigated: tumor size (n = 42 studies), number of nodules (n = 28), vascular invasion (n = 24), bile duct invasion (n = 6), growth pattern (n = 15), resection margin (n = 11), tumor location (n = 6), capsule (n = 2) and satellite (n = 1). Although the selected studies provided insightful data with notable prognostic performances, a lack of standardization and substantial gaps were noted in the report and the analysis of gross findings. This topic remains incompletely covered. While the available studies underscored the value of macroscopic variables in HCC prognostication, important lacks were also observed. Macroscopic characterization of HCC is likely an underexploited source of prognostic factors that must be actively explored by future multidisciplinary research.

Keywords: liver cancer, HCC, prognostication, gross, survival, recurrence
摘要:肝细胞癌(HCC)等肿瘤的宏观外观可定义为其表型,而表型事实上由其基因型决定。因此,HCC 的宏观特征不可能是随机的,而是反映了癌症的基因组特征,可以作为宝贵的信息来源,检索和利用这些信息来推断预后。本综述旨在全面概述有关 HCC 宏观特征预后价值的现有数据。共确定了 57 项符合合格标准的研究,包括接受肝切除术(LR;47 项研究,83%)或肝移植(LT;9 项研究,16%)的患者。对以下宏观变量进行了调查:肿瘤大小(42 项研究)、结节数量(28 项研究)、血管侵犯(24 项研究)、胆管侵犯(6 项研究)、生长模式(15 项研究)、切除边缘(11 项研究)、肿瘤位置(6 项研究)、囊肿(2 项研究)和卫星(1 项研究)。尽管所选研究提供的数据很有洞察力,预后效果显著,但在报告和对粗略结果的分析中,我们注意到缺乏标准化和存在很大差距。对这一主题的研究仍然不够全面。虽然现有研究强调了宏观变量在 HCC 预后中的价值,但也发现了重要的不足之处。HCC的宏观特征可能是预后因素中一个未被充分利用的来源,未来的多学科研究必须对其进行积极探索。关键词:肝癌、HCC、预后、大体、生存、复发
{"title":"Macroscopic Characterization of Hepatocellular Carcinoma: An Underexploited Source of Prognostic Factors","authors":"Stéphanie Gonvers, Sebastiao N Martins-Filho, André Hirayama, Julien Calderaro, Rebecca Phillips, Emilie Uldry, Nicolas Demartines, Emmanuel Melloul, Young Nyun Park, Valérie Paradis, Swan N Thung, Venancio Alves, Christine Sempoux, Ismail Labgaa","doi":"10.2147/jhc.s447848","DOIUrl":"https://doi.org/10.2147/jhc.s447848","url":null,"abstract":"<strong>Abstract:</strong> The macroscopic appearance of a tumor such as hepatocellular carcinoma (HCC) may be defined as its phenotype which is <em>de facto</em> dictated by its genotype. Therefore, macroscopic characteristics of HCC are unlikely random but rather reflect genomic traits of cancer, presumably acting as a valuable source of information that can be retrieved and exploited to infer prognosis. This review aims to provide a comprehensive overview of the available data on the prognostic value of macroscopic characterization in HCC. A total of 57 studies meeting eligible criteria were identified, including patients undergoing liver resection (LR; 47 studies, 83%) or liver transplant (LT; 9 studies, 16%). The following macroscopic variables were investigated: tumor size (n = 42 studies), number of nodules (n = 28), vascular invasion (n = 24), bile duct invasion (n = 6), growth pattern (n = 15), resection margin (n = 11), tumor location (n = 6), capsule (n = 2) and satellite (n = 1). Although the selected studies provided insightful data with notable prognostic performances, a lack of standardization and substantial gaps were noted in the report and the analysis of gross findings. This topic remains incompletely covered. While the available studies underscored the value of macroscopic variables in HCC prognostication, important lacks were also observed. Macroscopic characterization of HCC is likely an underexploited source of prognostic factors that must be actively explored by future multidisciplinary research. <br/><br/><strong>Keywords:</strong> liver cancer, HCC, prognostication, gross, survival, recurrence<br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"120 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140572715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy 肝切除术后接受经导管化疗栓塞治疗复发性肝细胞癌患者的提名图的开发与验证
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-04 DOI: 10.2147/jhc.s444682
Diyang Xie, Zhongchen Li, Jia Yuan, Xin Yin, Rongxin Chen, Lan Zhang, Zhenggang Ren
Purpose: This study aims to establish a prognostic nomogram for patients who underwent transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after hepatectomy.
Patients and Methods: Patients who underwent TACE for recurrent early- and middle-stage HCC after hepatectomy between 2009.01 and 2015.12 were included. Enrolled patients were randomly divided into training (n=345) and validation (n=173) cohorts according to a computer-generated randomized number. Independent factors for overall survival (OS) were determined and included in the nomogram based on the univariate and multivariate analyses of the training group. The nomogram was validated and compared to other prognostic models. Discriminative ability and predictive accuracy were determined using the Harrell C index (C-index), area under the receiver operating characteristic curve (AUROC), and calibration curve.
Results: The final nomogram was established based on four parameters including resection-to-TACE time interval, recurrent tumor diameter, recurrent tumor number, and AFP level. The C-indexes of the nomogram for predicting OS were 0.67 (95% CI 0.63– 0.70) and 0.71 (95% CI 0.68– 0.74) in the training and validation cohort respectively. The AUROCs for predicting the 1-year, 2-year and 3-year OS based on the nomogram were also superior to those of the other models. The calibration curve for 3-year survival showed a high congruence between the predicted and actual survival probabilities. According to the scores calculated by the nomogram, patients were stratified into three subgroups: high-risk (scoring ≥ 53 points), middle-risk (scoring ≥ 26 and < 53 points), and low-risk (scoring < 26 points) subgroups with a median OS of 10.1 (95% CI 0.63– 0.70), 20.3 (95% CI 17.5– 22.5) and 47.0 (95% CI 34.2– 59.8) months, respectively.
Conclusion: The proposed nomogram served as a new tool to predict individual survival in patients who underwent TACE for recurrent HCC after hepatectomy, with favorable performance and discrimination. For high-risk patients, treatment should be optimized beyond TACE alone based on the nomogram.

Keywords: hepatocellular carcinoma, transarterial chemoembolization, nomogram
目的:本研究旨在为接受经动脉化疗栓塞术(TACE)治疗肝切除术后复发性肝细胞癌(HCC)的患者建立预后提名图:纳入2009年1月至2015年12月期间因肝切除术后复发的早期和中期HCC而接受TACE治疗的患者。根据计算机生成的随机编号,入组患者被随机分为训练组(n=345)和验证组(n=173)。根据训练组的单变量和多变量分析,确定了总生存期(OS)的独立因素,并将其纳入提名图。对提名图进行了验证,并与其他预后模型进行了比较。使用哈雷尔C指数(C-index)、接收者工作特征曲线下面积(AUROC)和校准曲线确定了判别能力和预测准确性:最终的提名图是根据切除到TACE的时间间隔、复发肿瘤直径、复发肿瘤数目和AFP水平等四个参数制定的。在训练队列和验证队列中,提名图预测 OS 的 C 指数分别为 0.67(95% CI 0.63-0.70)和 0.71(95% CI 0.68-0.74)。基于提名图预测 1 年、2 年和 3 年 OS 的 AUROC 也优于其他模型。3 年生存率的校准曲线显示,预测的生存概率与实际生存概率高度一致。根据提名图计算的得分,患者被分为三个亚组:高危亚组(得分≥53分)、中危亚组(得分≥26分和< 53分)和低危亚组(得分< 26分),中位OS分别为10.1个月(95% CI 0.63-0.70)、20.3个月(95% CI 17.5-22.5)和47.0个月(95% CI 34.2-59.8):所提出的提名图是预测肝切除术后接受TACE治疗的复发性HCC患者个体生存率的新工具,具有良好的性能和区分度。对于高危患者,应根据提名图优化治疗,而不仅仅是TACE。 关键词:肝细胞癌、经动脉化疗栓塞、提名图
{"title":"Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy","authors":"Diyang Xie, Zhongchen Li, Jia Yuan, Xin Yin, Rongxin Chen, Lan Zhang, Zhenggang Ren","doi":"10.2147/jhc.s444682","DOIUrl":"https://doi.org/10.2147/jhc.s444682","url":null,"abstract":"<strong>Purpose:</strong> This study aims to establish a prognostic nomogram for patients who underwent transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after hepatectomy.<br/><strong>Patients and Methods:</strong> Patients who underwent TACE for recurrent early- and middle-stage HCC after hepatectomy between 2009.01 and 2015.12 were included. Enrolled patients were randomly divided into training (n=345) and validation (n=173) cohorts according to a computer-generated randomized number. Independent factors for overall survival (OS) were determined and included in the nomogram based on the univariate and multivariate analyses of the training group. The nomogram was validated and compared to other prognostic models. Discriminative ability and predictive accuracy were determined using the Harrell C index (C-index), area under the receiver operating characteristic curve (AUROC), and calibration curve.<br/><strong>Results:</strong> The final nomogram was established based on four parameters including resection-to-TACE time interval, recurrent tumor diameter, recurrent tumor number, and AFP level. The C-indexes of the nomogram for predicting OS were 0.67 (95% CI 0.63– 0.70) and 0.71 (95% CI 0.68– 0.74) in the training and validation cohort respectively. The AUROCs for predicting the 1-year, 2-year and 3-year OS based on the nomogram were also superior to those of the other models. The calibration curve for 3-year survival showed a high congruence between the predicted and actual survival probabilities. According to the scores calculated by the nomogram, patients were stratified into three subgroups: high-risk (scoring ≥ 53 points), middle-risk (scoring ≥ 26 and &lt; 53 points), and low-risk (scoring &lt; 26 points) subgroups with a median OS of 10.1 (95% CI 0.63– 0.70), 20.3 (95% CI 17.5– 22.5) and 47.0 (95% CI 34.2– 59.8) months, respectively.<br/><strong>Conclusion:</strong> The proposed nomogram served as a new tool to predict individual survival in patients who underwent TACE for recurrent HCC after hepatectomy, with favorable performance and discrimination. For high-risk patients, treatment should be optimized beyond TACE alone based on the nomogram.<br/><br/><strong>Keywords:</strong> hepatocellular carcinoma, transarterial chemoembolization, nomogram<br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"9 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140572589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis 肝动脉灌注化疗与经导管动脉化疗栓塞作为 MVI 阳性肝细胞癌手术后的辅助疗法:多中心倾向评分匹配分析
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-04 DOI: 10.2147/jhc.s453250
Yuhua Wen, Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wenping Lin, Wei Wei, Rongping Guo
Background: Microvascular invasion (MVI) is a significant pathological feature in hepatocellular carcinoma (HCC), adjuvant hepatic arterial infusion chemotherapy (a-HAIC) and adjuvant transcatheter arterial chemoembolization (a-TACE), are commonly used for HCC patients with MVI. This study aims to evaluate the efficacies of two adjuvant therapies after surgical treatment for HCC, compare them, and identify the significant factors.
Methods: Clinical data from two randomized controlled trials involving HCC patients with MVI after surgical treatment were retrospectively reviewed. Propensity score matching (PSM) analysis was performed to balance baseline differences between patients who received a-HAIC or a-TACE, and control groups who underwent hepatectomy alone. Disease-free survival (DFS) and overall survival (OS) rates were compared.
Results: In total of 549 patients were collected from two randomized controlled trials. Using the PSM and Kaplan-Meier method, the median DFS of the a-HAIC, a-TACE, and control groups was 63.2, 21.7, and 11.2 months (P< 0.05). The a-HAIC group show significantly better 1-, 3-, and 5-year OS rates compared to the a-TACE and control groups (96.3%, 80.0%, 72.8% vs 84.4%, 57.0%, 29.8% vs 84.5%, 62.8%, 53.4%, P< 0.05). But the OS rates of a-TACE and control groups showed no significant difference (P=0.279). Multivariate analysis identified a-HAIC (HR=0.449, P=0.000) and a-TACE (HR=0.633, P=0.007) as independent protective factors. For OS, a-HAIC (HR=0.388, P=0.003) was identified as an independent protective factor, too.
Conclusion: Compared to a-TACE and the control group, a-HAIC demonstrated greater benefits in preventing tumor recurrence and improving survival in HCC patients with MVI.

背景:微血管侵犯(MVI)是肝细胞癌(HCC)的一个重要病理特征,辅助肝动脉灌注化疗(a-HAIC)和辅助经导管动脉化疗栓塞(a-TACE)常用于有MVI的HCC患者。本研究旨在评估 HCC 手术治疗后两种辅助疗法的疗效,对其进行比较,并找出其中的重要因素:方法:回顾性研究了两项随机对照试验的临床数据,这些试验涉及手术治疗后伴有MVI的HCC患者。进行倾向评分匹配(PSM)分析,以平衡接受a-HAIC或a-TACE治疗的患者与仅接受肝切除术的对照组之间的基线差异。比较了无病生存率(DFS)和总生存率(OS):结果:两项随机对照试验共收集了 549 例患者。采用 PSM 和 Kaplan-Meier 法,a-HAIC 组、a-TACE 组和对照组的中位无病生存期分别为 63.2 个月、21.7 个月和 11.2 个月(P< 0.05)。与a-TACE组和对照组相比,a-HAIC组的1年、3年和5年OS率明显更高(96.3%、80.0%、72.8% vs 84.4%、57.0%、29.8% vs 84.5%、62.8%、53.4%,P< 0.05)。但a-TACE组与对照组的OS率无明显差异(P=0.279)。多变量分析发现,a-HAIC(HR=0.449,P=0.000)和a-TACE(HR=0.633,P=0.007)是独立的保护因素。对于OS,a-HAIC(HR=0.388,P=0.003)也被认为是一个独立的保护因素:结论:与 a-TACE 和对照组相比,a-HAIC 在预防肿瘤复发和改善 MVI HCC 患者的生存率方面具有更大的优势。
{"title":"Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis","authors":"Yuhua Wen, Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wenping Lin, Wei Wei, Rongping Guo","doi":"10.2147/jhc.s453250","DOIUrl":"https://doi.org/10.2147/jhc.s453250","url":null,"abstract":"<strong>Background:</strong> Microvascular invasion (MVI) is a significant pathological feature in hepatocellular carcinoma (HCC), adjuvant hepatic arterial infusion chemotherapy (a-HAIC) and adjuvant transcatheter arterial chemoembolization (a-TACE), are commonly used for HCC patients with MVI. This study aims to evaluate the efficacies of two adjuvant therapies after surgical treatment for HCC, compare them, and identify the significant factors.<br/><strong>Methods:</strong> Clinical data from two randomized controlled trials involving HCC patients with MVI after surgical treatment were retrospectively reviewed. Propensity score matching (PSM) analysis was performed to balance baseline differences between patients who received a-HAIC or a-TACE, and control groups who underwent hepatectomy alone. Disease-free survival (DFS) and overall survival (OS) rates were compared.<br/><strong>Results:</strong> In total of 549 patients were collected from two randomized controlled trials. Using the PSM and Kaplan-Meier method, the median DFS of the a-HAIC, a-TACE, and control groups was 63.2, 21.7, and 11.2 months (<em>P&lt;</em> 0.05). The a-HAIC group show significantly better 1-, 3-, and 5-year OS rates compared to the a-TACE and control groups (96.3%, 80.0%, 72.8% vs 84.4%, 57.0%, 29.8% vs 84.5%, 62.8%, 53.4%, P&lt; 0.05). But the OS rates of a-TACE and control groups showed no significant difference (<em>P</em>=0.279). Multivariate analysis identified a-HAIC (HR=0.449, <em>P</em>=0.000) and a-TACE (HR=0.633, <em>P</em>=0.007) as independent protective factors. For OS, a-HAIC (HR=0.388, <em>P</em>=0.003) was identified as an independent protective factor, too.<br/><strong>Conclusion:</strong> Compared to a-TACE and the control group, a-HAIC demonstrated greater benefits in preventing tumor recurrence and improving survival in HCC patients with MVI.<br/><br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"34 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140572800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine Learning Model Based on the Neutrophil-to-Eosinophil Ratio Predicts the Recurrence of Hepatocellular Carcinoma After Surgery 基于中性粒细胞与嗜酸性粒细胞比率的机器学习模型可预测肝细胞癌术后复发
IF 4.1 3区 医学 Q2 ONCOLOGY Pub Date : 2024-04-03 DOI: 10.2147/jhc.s455612
Guanming Shao, Yonghui Ma, Chao Qu, Ruiqian Gao, Chengzhan Zhu, Linlin Qu, Kui Liu, Na Li, Peng Sun, Jingyu Cao
Background: Circulating eosinophils are associated with tumor development. An eosinophil-related index, the neutrophil to eosinophil ratio (NER), can be used to predict the prognosis of patients with tumors. However, there is still a lack of efficient prognostic biomarkers for HCC. In this study, we aimed to investigate the predictive value of the NER and develop an optimal machine learning model for the recurrence of HCC patients. Patients and methods: A retrospective collection of 562 patients who underwent hepatectomy with a pathologic diagnosis of HCC was performed. The relationship between NER and progression-free survival (PFS) was investigated. We developed a new machine learning framework with 10 machine learning algorithms and their 101 combinations to select the best model for predicting recurrence after hepatectomy. The performance of the model was assessed by the area under the curve (AUC) of characteristics and calibration curves, and clinical utility was evaluated by decision curve analysis (DCA).
Results: Kaplan‒Meier curves showed that the PFS in the low NER group was significantly better than that in the high NER group. Multivariate Cox regression analysis showed that NER was an independent risk factor for recurrence after surgery. The random survival forests (RSF) model was selected as the best model that had good predictive efficacy and outperformed the TNM, BCLC, and CNLC staging systems.
Conclusion: The NER has good predictive value for postoperative recurrence in patients with hepatocellular carcinoma. Machine learning model based on NER can be used for accurate predictions.

背景:循环中的嗜酸性粒细胞与肿瘤的发展有关。嗜酸性粒细胞相关指数--中性粒细胞与嗜酸性粒细胞比值(NER)可用于预测肿瘤患者的预后。然而,目前仍缺乏有效的 HCC 预后生物标志物。在这项研究中,我们旨在调查嗜酸性粒细胞比值的预测价值,并为 HCC 患者的复发建立一个最佳的机器学习模型。患者和方法:我们回顾性地收集了562名接受肝切除术并经病理诊断为HCC的患者。我们研究了NER与无进展生存期(PFS)之间的关系。我们开发了一个新的机器学习框架,其中包含 10 种机器学习算法及其 101 种组合,以选择预测肝切除术后复发的最佳模型。通过特征曲线和校准曲线的曲线下面积(AUC)评估了模型的性能,并通过决策曲线分析(DCA)评估了临床实用性:Kaplan-Meier曲线显示,低NER组的PFS明显优于高NER组。多变量考克斯回归分析显示,NER是术后复发的独立风险因素。随机生存森林(RSF)模型被选为最佳模型,具有良好的预测效果,优于TNM、BCLC和CNLC分期系统:结论:NER 对肝细胞癌患者术后复发具有良好的预测价值。基于 NER 的机器学习模型可用于准确预测。
{"title":"Machine Learning Model Based on the Neutrophil-to-Eosinophil Ratio Predicts the Recurrence of Hepatocellular Carcinoma After Surgery","authors":"Guanming Shao, Yonghui Ma, Chao Qu, Ruiqian Gao, Chengzhan Zhu, Linlin Qu, Kui Liu, Na Li, Peng Sun, Jingyu Cao","doi":"10.2147/jhc.s455612","DOIUrl":"https://doi.org/10.2147/jhc.s455612","url":null,"abstract":"<strong>Background:</strong> Circulating eosinophils are associated with tumor development. An eosinophil-related index, the neutrophil to eosinophil ratio (NER), can be used to predict the prognosis of patients with tumors. However, there is still a lack of efficient prognostic biomarkers for HCC. In this study, we aimed to investigate the predictive value of the NER and develop an optimal machine learning model for the recurrence of HCC patients. Patients and methods: A retrospective collection of 562 patients who underwent hepatectomy with a pathologic diagnosis of HCC was performed. The relationship between NER and progression-free survival (PFS) was investigated. We developed a new machine learning framework with 10 machine learning algorithms and their 101 combinations to select the best model for predicting recurrence after hepatectomy. The performance of the model was assessed by the area under the curve (AUC) of characteristics and calibration curves, and clinical utility was evaluated by decision curve analysis (DCA).<br/><strong>Results:</strong> Kaplan‒Meier curves showed that the PFS in the low NER group was significantly better than that in the high NER group. Multivariate Cox regression analysis showed that NER was an independent risk factor for recurrence after surgery. The random survival forests (RSF) model was selected as the best model that had good predictive efficacy and outperformed the TNM, BCLC, and CNLC staging systems.<br/><strong>Conclusion:</strong> The NER has good predictive value for postoperative recurrence in patients with hepatocellular carcinoma. Machine learning model based on NER can be used for accurate predictions.<br/><br/>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"150 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140572586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Hepatocellular Carcinoma
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1